Report

ImmuPharma - Update

​Over 70 Lupus specialists together for the Lupuzor Investigators Meeting

Underlying
Immupharma

Immupharma is a drug discovery and development company. Co. is engaged in the development of novel drugs, largely based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. Co. is developing drug candidates within three technology platforms. Lupuzor™, a treatment for the autoimmune chronic inflammatory disease lupus, is Co.'s key product candidate. The other two platforms include Nucant platform (IPP-204106) for the treatment of cancer and ophthalmology, and a peptide technology platform for the treatment of diabetes.

Provider
Capital Access Group
Capital Access Group

Capital Access Group advises companies on effective engagement with investors. Our experienced team offers market-leading access with hard-to-reach investors, including smaller institutions, pension funds and private client fund managers. These under-serviced investors are located not only in London but across the regions of the UK and Europe. We have an unrivalled knowledge of this extensive audience, to whom our published research is distributed, as well as to larger institutions. We offer this service as part of an integrated investor communications strategy to promote a company’s investment story.

Our clients, ranging from AIM to FTSE 100 companies, benefit from our professional, long-term relationships with investors. Not only do we identify and target investors, we contact them directly and relay their views back to clients with analysis, interpretation and advice. This ensures that our clients are in control of their investor engagement. The objective is to improve the reach and engagement with investors, which in turn strengthens the share price.

Other Reports on these Companies
Other Reports from Capital Access Group

ResearchPool Subscriptions

Get the most out of your insights

Get in touch